Xin Zheng

Dr. Xin Zheng

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2018 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
XZXin Zheng
Xin Zheng
WWWeicong Wang
Weicong Wang
YZYanbao Zhang
Yanbao Zhang
YMYuxiang Ma
Yuxiang Ma
HZHongyun Zhao
Hongyun Zhao
JJJi Jiang
Ji Jiang

31 August 2022 in Polymer Degradation and Stability
Verified
Journal Article
Closed access
XSXuechun Sun
Xuechun Sun
JZJunpeng Zhuang
Junpeng Zhuang
XMXin Ma
Xin Ma
YTYan Tang
Yan Tang
MAMuhammad Mujahid Ali
Muhammad Mujahid Ali
ZDZhenxia Du
Zhenxia Du

1 April 2024 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
NLNing Lou
Ning Lou
XCXinge Cui
Xinge Cui
XLXinyuan Lin
Xinyuan Lin
RGRuyun Gao
Ruyun Gao
CXChi Xu
Chi Xu
XHXiaohong Han
Xiaohong Han
Background: Epidermal growth factor receptor (EGFR) T790M mutation is the standard predictive biomarker for third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. While not all T790M-positive patients respond to third-generation EGFR-TKIs and have a good prognosis, it necessitates novel tools to supplement EGFR genotype detection for predicting efficacy and stratifying EGFR-mutant patients with various prognoses. Mixture-of-experts (MoE) is designed to disassemble a large model into many small models. Meanwhile, it is also a model ensembling method that can better capture multiple patterns of intrinsic subgroups of enrolled patients. Therefore, the combination of MoE and Cox algorithm has the potential to predict efficacy and stratify survival in non-small cell lung cancer (NSCLC) patients with EGFR mutations. Methods: We utilized the electronic medical record (EMR) and pharmacokinetic parameters of 326 T790M-mutated NSCLC patients, including 283 patients treated with Abivertinib in phase I (n=177, for training) and II (n=106, for validation) clinical trials and an additional validation cohort 2 comprising 43 patients treated with BPI-7711. Furthermore, 18 patients underwent whole-exome sequencing for biological interpretation of CoxMoE. We evaluated the predictive performance for therapeutic response using the area under the curve (AUC) and the Concordance index (C-index) for progression-free survival (PFS). Results: CoxMoE exhibited AUCs of 0.73–0.83 for predicting efficacy defined by best overall response (BoR) and achieved C-index values of 0.64–0.65 for PFS prediction in training and validating cohorts. The PFS of 198 patients with a low risk [median, 6.0 (range, 1.0–23.3) months in the abivertinib treated cohort; median 16.5 (range, 1.4–27.4) months in BPI-7711 treated cohort] of being non-responder increased by 43% [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.40–0.78; P=0.0013] and 50% (HR, 0; 95% CI, 0–0; P=0.01) compared to those at high-risk [median, 4.2 (range, 1.0–35) months in the abivertinib treated cohort; median, 11.0 (range, 1.4–25.1) months in BPI-7711 treated cohort]. Additionally, activated partial thromboplastin time (APTT), creatinine clearance (Ccr), monocyte, and steady-state plasma trough concentration utilited to construct model were found significantly associated with drug resistance and aggressive tumor pathways. A robust correlation was observed between APTT and Ccr with PFS (log-rank test; P<0.01) and treatment response (Wilcoxon test; P<0.05), respectively. Conclusions: CoxMoE offers a valuable approach for patient selection by forecasting therapeutic response and PFS utilizing laboratory tests and pharmacokinetic parameters in the setting of early-phase clinical trials. Simultaneously, CoxMoE could predict the efficacy of third-generation EGFR-TKI non-invasively for T790M-positive NSCLC patients, thereby complementing existing EGFR genotype detection.

28 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
JJjianwei jianwei
jianwei jianwei
XZXin Zheng
Xin Zheng
XHXiaohong Han
Xiaohong Han
The new direct oral anticoagulants (DOACs) are increasingly used to treat and prevent thromboembolic disorders, and monitoring concentrations may be valuable in some special scenarios to prevent clinical adverse events. This study aimed to develop generic methods for the rapid and simultaneous analysis of four DOACs in human plasma and urine. Protein precipitation and one-step dilution were used to prepare the plasma and urine; the extracts were injected to ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for analysis. Chromatographic separation was performed on an Acquity™ UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm) with gradient elution of 7 min. A triple quadrupole tandem mass spectrometer with an electrospray ionization source was employed to analyze DOACs in a positive ion mode. The methods showed great linearity in the plasma (1~500 ng/mL) and urine (10~10,000 ng/mL) for all analytes (R2 ≥ 0.99). The intra- and inter-day precision and accuracy were within acceptance criteria. The matrix effect and extraction recovery were 86.5~97.5% and 93.5~104.7% in the plasma, while 97.0~101.9% and 85.1~99.5% in the urine. The stability of samples during the routine preparation and storage were within the acceptance criteria of less than ±15%. The methods developed were accurate, reliable, and simple for the rapid and simultaneous measurement of four DOACs in human plasma and urine, and successfully applied to patients and subjects with DOACs therapy for anticoagulant activity assessment.

1 May 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
XZXin Zheng
Xin Zheng
HGHuitao Gao
Huitao Gao
YZYanbao Zhang
Yanbao Zhang
XCXinge Cui
Xinge Cui
RJRanran Jia
Ranran Jia
HWHongyun Wang
Hongyun Wang

19 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
YYYue Yu
Yue Yu
HPHui-Yu Pan
Hui-Yu Pan
XZXin Zheng
Xin Zheng
FYFang YUAN
Fang YUAN
YZYing-Lin Zhou
Ying-Lin Zhou
Xin-xiang ZhangXin-xiang Zhang
Xin-xiang Zhang
Early cancer diagnosis is essential for successful treatment and prognosis, and modified nucleosides have attracted widespread attention as a promising group of cancer biomarkers. However, analyzing these modified nucleosides with an extremely low abundance is a great challenge, especially analyzing multiple modified nucleosides with a different abundance simultaneously. In this work, an ultrasensitive quantification method based on chemical labeling, coupled with LC-MS/MS analysis, was established for the simultaneous quantification of 5hmdC, 5fdC, 5hmdU and 5fdU. Additionally, the contents of 5mdC and canonical nucleosides could be obtained at the same time. Upon derivatization, the detection sensitivities of 5hmdC, 5fdC, 5hmdU and 5fdU were dramatically enhanced by several hundred times. The established method was further applied to the simultaneous detection of nine nucleosides with different abundances in about 2 μg genomic DNA of breast tissues from 20 breast cancer patients. The DNA consumption was less than other overall reported quantification methods, thereby providing an opportunity to monitor rare, modified nucleosides in precious samples and biology processes that could not be investigated before. The contents of 5hmdC, 5hmdU and 5fdU in tumor tissues and normal tissues adjacent to the tumor were significantly changed, indicating that these three modified nucleosides may play certain roles in the formation and development of tumors and be potential cancer biomarkers. While the detection rates of 5hmdC, 5hmdU and 5fdU alone as a biomarker for breast cancer samples were 95%, 75% and 85%, respectively, by detecting these three cancer biomarkers simultaneously, two of the three were 100% consistent with the overall trend. Therefore, simultaneous detection of multiple cancer biomarkers in clinical samples greatly improved the accuracy of cancer diagnosis, indicating that our method has great application potential in clinical multidimensional diagnosis.